Oh, what a surprise, another day, another molecule doing something in the body we didn’t fully understand until now. This time, it’s the turn of PBK phosphorylation to take the spotlight in the never-ending saga of “Why is this thing growing where it shouldn’t?” starring prolactinomas, the most popular of the pituitary neuroendocrine tumors (PitNETs). Because, you know, they just love to invade personal space like an unwelcome guest at a party.

So, the researchers, in their infinite wisdom, decided to dive deep into the molecular soap opera to figure out why these tumors are so clingy. And guess what they found? PBK, when it gets a little phosphorylation action from its buddy cyclin-dependent kinase 5 (CDK5) at a specific spot called Thr9, decides it’s time to party. This phosphorylation is like giving PBK a stability boost, making it feel all invincible, which in turn tells GH3 cells (a type of cell that’s just living its best life until it gets these bad signals) to proliferate and embrace epithelial-mesenchymal transition (EMT) progression. It’s like telling cells, “Hey, why not travel and multiply? YOLO.”

But wait, there’s more! PBK, now feeling all powerful with its phosphorylation, affects p38 (another molecule just trying to do its job), reducing its phosphorylation. It’s like PBK is saying, “No, p38, you sit this one out.” And, as if we needed more drama, pPBK-T9 (the phosphorylated PBK at Thr9, for those not keeping up) is found strutting its stuff in invasive PitNETs, correlating with invasion levels like it’s the main character.

In conclusion, the phosphorylation of PBK at Thr9 by CDK5 is basically the molecular equivalent of giving cells the green light to multiply and spread, making it a key player in the proliferation and EMT progression in prolactinomas. Because, of course, we needed another molecule complicating things in the already complex world of cellular biology.